Compare SXI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXI | RCUS |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 1994 | 2018 |
| Metric | SXI | RCUS |
|---|---|---|
| Price | $247.48 | $18.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $332.40 | $41.00 |
| AVG Volume (30 Days) | 137.3K | ★ 2.2M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | ★ 86.85 | N/A |
| EPS | ★ 8.67 | N/A |
| Revenue | ★ $604,535,000.00 | $247,000,000.00 |
| Revenue This Year | $6.96 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $28.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $215.62 | $17.43 |
| 52 Week High | $363.89 | $31.74 |
| Indicator | SXI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 29.63 |
| Support Level | $238.78 | $17.97 |
| Resistance Level | $264.25 | $24.46 |
| Average True Range (ATR) | 10.57 | 1.61 |
| MACD | -2.50 | -0.32 |
| Stochastic Oscillator | 30.66 | 12.74 |
Standex International Corp is a diversified industrial manufacturer with multiple products and services that are used in diverse commercial and industrial markets. The Company operates in four broad business segments: Electronics, Aerospace & Defense (A&D), Scientific, and Engraving & Hydraulics. The Electronics segment generates maximum revenue and is engaged in manufacturing and selling electronic components for applications throughout the end-user market spectrum. The Company has operations in the United States, Europe, Canada, Japan, Singapore, Mexico, Turkey, India, and China. The Company generates maximum revenue from the United States.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.